Program
bofanglutide
Also written as “GZR18”, “GZR18 injection” and “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticals | 237 open or running | phase 3since Dec 5, 2024 | Feb 25, 2022 | Jun 30, 2027phase 3 · NCT07150975 |
| Carnot Laboratories | 22 open or running | phase 3since May 24, 2026 | May 24, 2026 | Oct 2027phase 3 · NCT07628985 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 25, 2022.
- Feb 5, 20244 phase 2 studiesGan & Lee Pharmaceuticals · NCT06256562, NCT06256549, NCT06256536 and 1 more
- Aug 8, 20243 phase 1 studiesGan & Lee Pharmaceuticals · NCT06554054, NCT06548997, NCT06548945
- Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT06670209 · 32 planned
- Dec 5, 2024Phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT06728124 · 640 enrolled · China
- Dec 16, 2024Phase 2 study in ObesityGan & Lee Pharmaceuticals · NCT06737042 · 326 enrolled · United States
- Jan 3, 20252 phase 3 studies in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT06778967, NCT06777238
- Jun 27, 2025Phase 2 study in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT07055386 · 90 enrolled · China
- Jul 9, 2025Phase 1 study in OverweightGan & Lee Pharmaceuticals · NCT07119450 · 6 enrolled · China
- Aug 6, 20253 phase 1 studies in ObesityGan & Lee Pharmaceuticals · NCT07128888, NCT07141030, NCT07144098
- Aug 27, 2025Phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT07150975 · 420 planned · China
- Nov 20, 2025Phase 3 study in OverweightGan & Lee Pharmaceuticals · NCT07292441 · 224 enrolled · China
- Jan 5, 2026Phase 1 study in Obesity&T2DGan & Lee Pharmaceuticals · NCT07355738 · 266 enrolled · China
- Mar 20, 20262 phase 3 studies in Sleep Apnea, ObstructiveGan & Lee Pharmaceuticals · NCT07493057, NCT07501832
- May 24, 2026Carnot Laboratories's first studies: 2 phase 3 studiesNew to Carnot LaboratoriesCarnot Laboratories · NCT07628985, NCT07622810
Ahead
- Jun 30, 2027Primary completion: phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT07150975
- Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Carnot Laboratories · NCT07628985
- Nov 14, 2027Primary completion: phase 3 study in Sleep Apnea, ObstructiveGan & Lee Pharmaceuticals · NCT07493057
- Dec 2027Primary completion: phase 3 study in ObesityCarnot Laboratories · NCT07622810
TargetBeta
“Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07628985Diabetes Mellitus, Type 2 · Mexico | 3 | Not yet recruiting | Carnot Laboratories | Oct 2027 | 374 |
| NCT07622810Obesity · Mexico | 3 | Not yet recruiting | Carnot Laboratories | Dec 2027 | 352 |
| NCT07501832Sleep Apnea, Obstructive · China | 3 | Recruiting | Gan & Lee Pharmaceuticals | Sep 28, 2028 | 140 |
| NCT07493057Sleep Apnea, Obstructive · China | 3 | Recruiting | Gan & Lee Pharmaceuticals | Nov 14, 2027 | 140 |
| NCT07355738Obesity&T2D · China | 1 | Completed | Gan & Lee Pharmaceuticals | May 22, 2026 | 266 |
| NCT07292441Overweight · China | 3 | Completed | Gan & Lee Pharmaceuticals | Sep 22, 2026 | 224 |
| NCT07150975Obesity · China | 3 | Recruiting | Gan & Lee Pharmaceuticals | Jun 30, 2027 | 420 |
| NCT07144098Obesity · China | 1 | Completed | Gan & Lee Pharmaceuticals | Apr 7, 2026 | 24 |
| NCT07141030Obesity · China | 1 | Completed | Gan & Lee Pharmaceuticals | Oct 20, 2025 | 32 |
| NCT07128888Obesity · China | 1 | Completed | Gan & Lee Pharmaceuticals | Apr 13, 2026 | 60 |
| NCT07119450Overweight · China | 1 | Completed | Gan & Lee Pharmaceuticals | Aug 13, 2025 | 6 |
| NCT07055386Diabetes Mellitus, Type 2 · China | 2 | Active, not recruiting | Gan & Lee Pharmaceuticals | Jun 28, 2026 | 90 |
| NCT06777238Diabetes Mellitus, Type 2 · China | 3 | Completed | Gan & Lee Pharmaceuticals | Jul 30, 2026 | 274 |
| NCT06778967Diabetes Mellitus, Type 2 · China | 3 | Completed | Gan & Lee Pharmaceuticals | Sep 18, 2026 | 1,133 |
| NCT06737042Obesity · United States | 2 | Completed | Gan & Lee Pharmaceuticals | Feb 27, 2026 | 326 |
| NCT06728124Obesity · China | 3 | Completed | Gan & Lee Pharmaceuticals | Mar 26, 2026 | 640 |
| NCT06670209Diabetes Mellitus, Type 2 | 1 | Not yet recruiting | Gan & Lee Pharmaceuticals | Mar 19, 2025 | 32 |
| NCT06554054Diabetes Mellitus, Type 2 · China | 1 | Active, not recruiting | Gan & Lee Pharmaceuticals | Dec 9, 2024 | 92 |
| NCT06548997Diabetes Mellitus, Type 2 · China | 1 | Completed | Gan & Lee Pharmaceuticals | Oct 20, 2022 | 57 |
| NCT06548945Overweight · China | 1 | Completed | Gan & Lee Pharmaceuticals | Aug 14, 2023 | 16 |
| NCT06256562Obesity · China | 2 | Completed | Gan & Lee Pharmaceuticals | Jun 5, 2024 | 340 |
| NCT06256549Diabetes Mellitus, Type 2 · China | 2 | Active, not recruiting | Gan & Lee Pharmaceuticals | Jul 20, 2024 | 272 |
| NCT06256536Obesity · China | 2 | Completed | Gan & Lee Pharmaceuticals | Oct 22, 2023 | 60 |
| NCT06256523Diabetes Mellitus, Type 2 · China | 2 | Completed | Gan & Lee Pharmaceuticals | Sep 28, 2023 | 72 |
| NCT05328726Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gan & Lee Pharmaceuticals | Feb 9, 2023 | 24 |
How it is read
Names in the registry
- “GZR18”, 13 entries
- “GZR18 injection”, 8 entries
- “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”, 1 entry
- “GZR18 injection A”, 1 entry
- “GZR18 injection B”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 10 studies
- Sleep Apnea, Obstructive, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.